TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Recurrent Prostate Cancer
Source: Prostate Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer
Treatment options for patients with recurrent prostate cancer include:
Source links and citations
Chemotherapy for hormone-sensitive or hormone-resistant prostate cancer.
Source links and citations
Immunotherapy.
Source links and citations
Radiopharmaceutical therapy.
Source links and citations
Radiopharmaceutical therapy.
Alpha emitter radiation therapy.
Source links and citations
Radiopharmaceutical therapy.
Beta emitter radiation therapy.
Source links and citations
Poly (ADP-ribose) polymerase (PARP) inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants.
Source links and citations
Poly (ADP-ribose) polymerase (PARP) inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants.
Olaparib.
Source links and citations
Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants.
Source links and citations
Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants.
PARP inhibitors as first-line therapy for men with mCRPC and BRCA1 or BRCA2 variants.
Source links and citations
Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants.
PARP inhibitors as first-line therapy for men with mCRPC and variants in homologous recombination repair genes.
Continue within this section
Preserved source evidence · Not medical advice